Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5′-phosphatase interaction with c-Abl

Role of phosphodiesterases in the shaping of sub-plasma-membrane cAMP oscillations and pulsatile insulin secretion

(2012) G. Tian et al.   JOURNAL OF CELL SCIENCE

Strategic combination therapy overcomes tyrosine kinase coactivation in adrenocortical carcinoma

(2012) Chi-Iou Lin et al.   SURGERY

A genetically engineered human pancreatic β cell line exhibiting glucose-inducible insulin secretion

(2011) Philippe Ravassard et al.   JOURNAL OF CLINICAL INVESTIGATION

Deletion of Pten in Pancreatic  -Cells Protects Against Deficient  -Cell Mass and Function in Mouse Models of Type 2 Diabetes

(2010) L. Wang et al.   DIABETES

SHIP2 and its involvement in various diseases

(2010) Akira Suwa et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Plasma Adiponectin Levels Are Markedly Elevated in Imatinib-Treated Chronic Myeloid Leukemia (CML) Patients: A Mechanism for Improved Insulin Sensitivity in Type 2 Diabetic CML Patients?

(2010) Stephen Fitter et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A Protein Tyrosine Kinase Inhibitor, Imatinib Mesylate (Gleevec), Improves Erectile and Vascular Function Secondary to a Reduction of Hyperglycemia in Diabetic Rats

(2010) Serap Gur et al.   Journal of Sexual Medicine

Genetics, pathogenesis and clinical interventions in type 1 diabetes

(2010) Jeffrey A. Bluestone et al.   NATURE

Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice

(2010) Nicole M Agostino et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Specific Tyrosine Phosphorylations Mediate Signal-Dependent Stimulation of SHIP2 Inositol Phosphatase Activity, while the SH2 Domain Confers an Inhibitory Effect To Maintain the Basal Activity

(2009) Nagendra K. Prasad et al.   BIOCHEMISTRY

Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes

(2009) Dariush Mokhtari et al.   CLINICAL SCIENCE

Imatinib Mesylate Reduces Endoplasmic Reticulum Stress and Induces Remission of Diabetes in db/db Mice

(2009) M. S. Han et al.   DIABETES

Lack of β-catenin in early life induces abnormal glucose homeostasis in mice

(2009) S. Dabernat et al.   DIABETOLOGIA

Stromal cell-derived factor-1 promotes survival of pancreatic beta cells by the stabilisation of beta-catenin and activation of transcription factor 7-like 2 (TCF7L2)

(2009) Z. Liu et al.   DIABETOLOGIA

Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia

(2009) Stefania Mariani et al.   LEUKEMIA RESEARCH

Potential of Small Molecule Protein Tyrosine Kinase Inhibitors as Immunomodulators and Inhibitors of the Development of Diabetes

(2009) Peter J. Little et al.   TheScientificWorldJOURNAL

Glucose-Induced Cyclic AMP Oscillations Regulate Pulsatile Insulin Secretion

(2008) Oleg Dyachok et al.   Cell Metabolism

Glucagon-like Peptide-1 Activation of TCF7L2-dependent Wnt Signaling Enhances Pancreatic Beta Cell Proliferation

(2008) Zhengyu Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr–Abl transformed cells via the alteration of signaling complex and the receptor turnover

(2008) A Koch et al.   ONCOGENE

Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice

(2008) C. Louvet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet

(2007) Robert Hägerkvist et al.   CLINICAL SCIENCE

Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenic leukemia (CML)

(2007) Apostolos Tsapas et al.   LEUKEMIA RESEARCH